Currently viewing: Biopharma Clear Filter
07/07/21
NEA's Q&A series is focused on the company building journey and the impactful work of leaders across NEA’s portfolio. Our goal is to shed light on…
By: Erica Sunkin
Biopharma, Healthcare, Pharmaceuticals, Digital Health
Read Content08/19/19
*Interview of Sara Nayeem by Maya De La Rosa-Cohen; originally published as part of the Capsule 'Dear Doctor' Series, which highlights women…
Biopharma, Healthcare, Venture Capital
Read Content01/03/19
For the past ten years I have been a biopharma investor at NEA, and in that time I have witnessed the drug industry truly enter the genomic age. With…
Biopharma, Healthcare, Investment, Pharmaceuticals, Venture Capital
Read Content11/23/15
3.9 million births were recorded in the US in 2013, according to the CDC, down 1% from previous years. Of those, 11.4% were premature births.…
By: Ed Mathers
Biopharma
Read Content10/28/15
C-3PO: “Sir, the possibility of successfully navigating an asteroid field is approximately three thousand, seven hundred and twenty to one.” Han…
Biopharma
Read Content01/07/15
Today Vtesse, a newly formed biopharma company, announced that it has raised $25 million to develop novel treatments for rare diseases. It’s a…
Biopharma, Healthcare, Investment, Strategy
Read ContentSubscribe to our newsletter for the latest from NEA and highlights from across our portfolio. We promise to keep you informed without cluttering your inbox. We're looking forward to staying in touch!